S&P Futures
3,847.50+38.25(+1.00%)Dow Futures
31,200.00+288.00(+0.93%)Nasdaq Futures
13,085.25+174.25(+1.35%)
AVROBIO, Inc. (AVRO)
11.16 +0.16 (1.45%)
Pre-Market: 5:42AM EST
Chart Events
Performance Outlook
| Previous Close | 11.00 |
| Open | 10.99 |
| Bid | 11.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 10.59 - 11.16 |
| 52 Week Range | 9.76 - 23.50 |
| Volume | 844,680 |
| Avg. Volume | 539,570 |
| Market Cap | 455.961M |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | Mar 15, 2021 - Mar 19, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.60 |
Fair Value
Related Research
- Business Wire
AVROBIO to Present at Three Upcoming Investor Conferences in March
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.
- Benzinga
Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study
Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed. The company also announced six-month data from the first patient dosed in the Phase 1/2 trial of AVR-RD-02, an ex vivo lentiviral gene therapy for Gaucher disease type 1, showing substantial improvement over pre-gene therapy enzyme replacement therapy baseline in key biomarkers at six months post-gene therapy. Plasma chitotriosidase levels decreased 49%, and toxic metabolite lyso-Gb1 levels dropped 44% in the first patient at six months post-gene therapy, compared to the patient's pre-gene therapy ERT baseline levels. Additionally, preliminary data from the investigator-sponsored Phase 1/2 trial of AVR-RD-04 showed that all three cystinosis patients demonstrated strong data across multiple measures, including substantial improvement in photophobia in the first patient 12 months post-gene therapy. All patients remained off cysteamine pills, and eye drops, with trial enrollment completion expected this year. The Investor and analyst presentation is scheduled today at 8 a.m. ET. Price Action: AVRO jumped 19.6% at $20.46 in premarket trading on the last check Monday. See more from BenzingaClick here for options trades from BenzingaWell Health Scoops Up CRH Medical For Per Share; CRHM Shares SkyrocketNanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Business Wire
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is the trial’s primary efficacy endpoint and has previously been used by the U.S. Food and Drug Administration (FDA) in evaluating and approving treatments for Fabry disease.
